Pharmaceutical

PD-(L)1 Resistance Hope PD-1 Immunotherapy Oncology ADC Explore how LRRC15+ CAFs contribute to PD-1 resistance, the role of LRRC15 in tumor immunity, and emerging therapies targeting LRRC15 and PD-1 to improve cancer immunotherapy outcomes.
The Cost of Attacking the Pharmaceutical Industry Trump Market Trend FDA NIH Trump's policies during his second term have rocked the U.S. scientific community, slashing NIH funding, threatening pharmaceutical innovation, and reshaping the global research landscape amid rising concerns about America's future in science.
Roche's Q1 2025 Financial report Financial statements Market Trend Roche Roche Q1 2025 financial results show 6% revenue growth, driven by strong demand for innovative drugs and diagnostics. China leads international growth, while the company makes strategic investments in the US and global R&D.
Merck's Q1 2025 Financial report Financial statements Market Trend Merck Merck's Q1 2025 earnings show a 2% decline in revenue, with strong growth in KEYTRUDA and animal health products. The company faces short-term challenges but continues to drive innovation in its R&D pipeline.
Sanofi's Q1 2025 Financial report Sanofi Financial statements Market Trend Sanofi's Q1 2025 report shows a 9.7% sales growth, driven by Dupixent and innovative drugs. The company confirms full-year guidance with strong performance in immunology, rare diseases, and vaccines.
BMS's Q1 2025 Financial report Market Trend Financial statements BMS Bristol Myers Squibb Bristol Myers Squibb Q1 2025 earnings: revenue down 6% YoY, but strong product performance drives EPS growth. Full-year guidance raised. Highlights include Opdivo, Reblozyl, and Breyanzi.
Major Breakthrough! These Targets Entered Clinical Trials for the First Time in 2025 Biopharmaceutical ACK1 CD83 Discover the groundbreaking entry of ACK1 and CD83 into clinical trials in 2025. Explore their potential in treating CRPC and AML, and how these novel targets may reshape the future of cancer therapy and pharmaceutical innovation.
Layoffs, Rivals, and the Future of Ocular Therapeutix Ocular Therapeutix Ocular Therapeutix is advancing retinal disease treatments with its ELUTYX hydrogel platform, featuring long-acting implants like AXPAXLI™ for wet AMD and DEXTENZA® for post-surgical inflammation and allergic conjunctivitis.
Innovative Drugs: The Changing Times FDA ADC Recent advancements in ADC therapies are reshaping cancer treatment. AstraZeneca and Gilead's breakthroughs in first-line therapies for breast and TNBC cancers mark a new era in innovative drug development.
Biotech Drives Innovation, Big Pharma Creates Blockbusters Market Trend Explore how Biotech drives innovation and Big Pharma delivers blockbusters in the FIC drug landscape. Discover key insights on collaboration, commercialization, and the future of China's pharmaceutical industry.